Lenalidomide (Revlimid®)

Assessment Status Rapid Review Complete
Drug Lenalidomide
Brand Revlimid®
Indication For the treatment of adult patients with previously untreated multiple myelomas (MM) who are not eligible for transplant (licence extension).
Assessment Process
Rapid review commissioned 05/10/2015
Rapid review completed 20/11/2015
Rapid review outcome Full Pharmacoeconomic Assessment Recommended at the submitted price

Approved following confidential price negotiation for lenalidomide across all licensed indications (January 2018).